GSA Capital Partners LLP Grows Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

GSA Capital Partners LLP raised its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 154.7% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 219,918 shares of the company's stock after buying an additional 133,577 shares during the period. GSA Capital Partners LLP owned about 0.21% of Intellia Therapeutics worth $1,564,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Ensign Peak Advisors Inc raised its position in shares of Intellia Therapeutics by 2.9% during the 4th quarter. Ensign Peak Advisors Inc now owns 39,169 shares of the company's stock valued at $457,000 after buying an additional 1,100 shares during the period. Virtus ETF Advisers LLC lifted its stake in Intellia Therapeutics by 47.7% during the fourth quarter. Virtus ETF Advisers LLC now owns 5,242 shares of the company's stock worth $61,000 after purchasing an additional 1,692 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in Intellia Therapeutics by 28.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,148 shares of the company's stock worth $95,000 after purchasing an additional 1,808 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in Intellia Therapeutics during the fourth quarter worth $25,000. Finally, Kennedy Capital Management LLC lifted its stake in Intellia Therapeutics by 22.7% during the fourth quarter. Kennedy Capital Management LLC now owns 12,847 shares of the company's stock worth $150,000 after purchasing an additional 2,381 shares in the last quarter. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Intellia Therapeutics Price Performance

Intellia Therapeutics stock traded down $0.15 during mid-day trading on Friday, reaching $11.49. The company had a trading volume of 5,094,694 shares, compared to its average volume of 4,612,395. Intellia Therapeutics, Inc. has a 1 year low of $5.90 and a 1 year high of $24.25. The company has a market capitalization of $1.19 billion, a P/E ratio of -2.20 and a beta of 2.31. The stock's 50-day simple moving average is $10.25 and its 200-day simple moving average is $9.44.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($1.10) earnings per share for the quarter, topping analysts' consensus estimates of ($1.26) by $0.16. Intellia Therapeutics had a negative net margin of 1,154.10% and a negative return on equity of 56.06%. The business had revenue of $16.63 million during the quarter, compared to analysts' expectations of $11.39 million. During the same period last year, the company posted ($1.12) EPS. The company's revenue was down 42.6% on a year-over-year basis. On average, equities analysts forecast that Intellia Therapeutics, Inc. will post -5.07 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have commented on NTLA. Citigroup decreased their price target on Intellia Therapeutics from $14.00 to $10.00 and set a "neutral" rating on the stock in a research note on Friday, May 9th. Guggenheim cut their price objective on Intellia Therapeutics from $55.00 to $45.00 and set a "buy" rating on the stock in a research report on Monday, May 12th. Canaccord Genuity Group cut their price objective on Intellia Therapeutics from $74.00 to $54.00 and set a "buy" rating on the stock in a research report on Tuesday, June 3rd. Chardan Capital reaffirmed a "buy" rating and set a $68.00 price objective on shares of Intellia Therapeutics in a research report on Friday, May 9th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $30.00 price objective on shares of Intellia Therapeutics in a research report on Monday, June 16th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $33.37.

Insider Buying and Selling at Intellia Therapeutics

In other news, EVP Edward J. Dulac III sold 7,462 shares of the firm's stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $14.02, for a total transaction of $104,617.24. Following the completion of the transaction, the executive vice president directly owned 106,062 shares of the company's stock, valued at $1,486,989.24. This trade represents a 6.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last three months, insiders have sold 12,534 shares of company stock worth $153,837. Company insiders own 3.10% of the company's stock.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.